ReviewGland surgery2026
Computed tomography quantitative imaging features for pancreatic ductal adenocarcinoma after neoadjuvant therapy: a narrative review.
Review in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies. Neoadjuvant therapy (NAT) has been routinely used in borderline resectable and locally advanced cases, now it is also gradually expanding to some resectable cases. Post-NAT assessment on computed tomography (CT) is intrinsically challenging, as therapy-induced stromal remodeling, fibrosis, and inflammation may obscure viable tumor, while size-based criteria correlate poorly with pathological response and survival. This narrative review aims to synthesize CT-based quantitative imaging features for PDAC after NAT and to clarify how these imaging biomarkers may support clinically relevant multidisciplinary decision-making. Methods: A narrative review was conducted using a three-layer literature identification strategy. A primary search of PubMed and Web of Science Core Collection was performed on 7 April 2026 to identify English-language articles published from 2013 to 2026. The search focused on PDAC, NAT, CT, and CT-derived quantitative approaches, including radiomics, perfusion CT, dual-energy/spectral CT, and photon-counting CT (PCCT), together with clinically relevant endpoints such as response, resectability, margin status, survival, recurrence, and prognosis. Targeted supplementary retrieval and manual anchor retrieval were additionally used for key reviews, foundational pathology and tumor microenvironment (TME) references, complementary magnetic resonance imaging (MRI) and positron emission tomography (PET) literature, and methodological framework papers. Key Content and Findings: Quantitative CT features after NAT can be organized around four multidisciplinary team (MDT) decisions: assessment of tumor-vessel interface resectability and the probability of margin-negative (R0) resection, NAT stewardship, surgical-window timing, and early recurrence risk stratification. The most informative measurement layers include interpretable morphologic and enhancement-based metrics, longitudinal delta features, perfusion-derived functional parameters, iodine- and material-sensitive metrics from energy-resolved CT, and multi-compartment radiomics or habitat analysis. Conclusions: Building on this evidence, we outline a pragmatic, CT-centric measurement ladder that progresses from interpretable enhancement and iodine metrics to interface focused features and habitat-level heterogeneity, aiming to reduce inter-reader variability and improve multicenter reproducibility, with MRI and PET positioned as complementary modalities for future multimodal validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.